舒泰神(300204.SZ)：STSP-0601审评审批并未结束

Core Viewpoint - The company Shutaishen (300204.SZ) has submitted a conditional listing application for its injectable STSP-0601, which was accepted by the National Medical Products Administration (NMPA) in June 2025 and is currently undergoing the normal review process [1] Group 1 - The priority review application for STSP-0601 has a review timeline of 130 days [1] - Preliminary reviews by various professional departments have been completed, and the application has entered the next stage [1] - The timing for the Center for Drug Evaluation (CDE) is currently paused, indicating that the review process is proceeding normally and has not concluded [1]